Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Stock Information for Immunic Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immunic Inc.

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
Immunic to Participate in Investor, Scientific and Industry Conferences in June
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. Announces Proposed Public Offering
Immunic to Participate in Scientific and Industry Conferences in May
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.